エイズと臨床研究のジャーナル

A booster dose is required for people with HIV-1 who have undetectable anti-HBs antibodies

Abstract

Ferosr Mesder

HIV-1 infection remains a global health challenge, affecting millions of people worldwide. While much progress has been made in managing and treating HIV-1, co-infections and comorbidities continue to pose significant concerns. One such issue is the immune response to Hepatitis B Virus (HBV) vaccination in HIV-1-infected individuals. This article explores the phenomenon of undetectable anti-HBs antibodies in HIV-1-infected individuals and discusses the potential need for booster doses of HBV vaccine to ensure long-term protection. The quest for an effective HIV vaccine has been one of the greatest challenges in modern medicine.